Gault Cheryl 4

What Happened
Cheryl Gault, Chief Operating Officer of Rapport Therapeutics (RAPP), received a grant/award of 132,000 derivative shares (reported as acquisition at $0.00) on February 2, 2026. The filing classifies the transaction as an award/grant (code A) and records $0.00 as the acquisition price, indicating a compensation grant rather than an open‑market purchase. The filing does not state an immediate cash value or post-transaction beneficial ownership.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely filing).
• Transaction type/code: Award/Grant (A) — reported as a derivative instrument.
• Shares granted: 132,000; acquisition price reported: $0.00 (grant, not a cash purchase).
• Vesting/exercise: Per footnote, the shares underlying this option vest and become exercisable in 48 equal monthly installments beginning January 1, 2026, subject to continued service.
• Shares owned after transaction: Not specified in the filing.
• No indication of immediate sale, cashless exercise, 10b5-1 plan, or tax withholding in this filing.

Context
This appears to be a standard equity compensation award to a senior executive that vests over four years (monthly), intended as a retention/long‑term incentive. Because the award is a derivative grant (an option that must vest to become exercisable), it does not represent an immediate purchase or sale of stock and therefore provides limited near‑term signal about the insider’s trading intentions. Monitor future Form 4s for vesting/exercise or any subsequent sales.